Histocompatibility Leukocyte Antigen (HLA)-A*2402 and A*0201 Restricted Peptide Vaccine Therapy in Patients With Neovascular Maculopathy
VEGF receptor 1 and 2 are essential targets to pathogenic angiogenesis, and we identified
that peptides derived from these receptors significantly induce the effective tumor specific
CTL response in vitro and vivo. According to these findings, in this trial, we evaluate the
safety, immunological and clinical response of those peptides. Patients will be vaccinated
once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide
(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection. In the
study, our primary aim is to evaluate the safety and tolerability of these peptide vaccine.
The second aim is evaluate the immunological and clinical response of this vaccine therapy.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety of this trial will be assessed based on National Cancer Institute-Common Toxicity Criteria,(NCI-CTC) version3. In case grade 4 or more complications occur, we will report the case to the review board within 14 days.
Kohji Nishida, MD, PhD
Chair of Ophthalmology, Osaka University Medical School
Japan: Ministry of Health, Labor and Welfare